Cited by 164PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index.

PARP Inhibitors in Ovarian Cancer

Open access

Mittica, Gloria, Ghisoni, Eleonora, Giannone, Gaia, Genta, Sofia, Aglietta, Massimo, Sapino, Anna, Valabrega, Giorgio·2018·Recent Patents on Anti-Cancer Drug Discovery

DOI 10.2174/1574892813666180305165256

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients. OBJECTIVES: The study aimed to highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis. METHODS: We performed a review on Pubmed using 'ovarian cancer' and the name of each PARPi (PARP inhibitor) discussed in the review as Medical Subject Headings (MeSH) keywords. The same search was performed on "clinicaltrial.gov" to identify ongoing clinical trials and on "google. com/patents" and "uspto.gov" for recent patents exploring PARPIs in ovarian cancer. RESULTS: Olaparib, Niraparib and Rucaparib are already approved for the treatment of recurrent EOC and their indications are partially overlapping. Talazoparib and Veliparib are promising PARPis, but currently under investigation in early phase trials. Several studies are evaluating PARPis in monotherapy or in associations, in a wide range of settings (i.e. first line, neoadjuvant, platinum-sensitive and resistant disease). CONCLUSION: PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC.

Integrity signals

Registry

Crossref · 10.2174/1574892813666180305165256

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,893
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,891
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,572
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,437
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,193
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Gelmon, K. A., Tischkowitz, M. D., MacKay, H. J., Swenerton, K. D., Robidoux, A., Tonkin, K. S., Hirte, H. W., Huntsman, D. D., Clemons, M. J., Gilks, C. B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,130
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,075
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 975
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
Moynahan, M. E., & Jasin, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2851 · Cited by 959
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P. G., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 915
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Replication stress links structural and numerical cancer chromosomal instability
Burrell, R. A., McClelland, S. E., Endesfelder, D., Groth, P., Weller, M.-C., Shaikh, N., Domingo, E., Kanu, N., Dewhurst, S. M., Gronroos, E. C., et al. (2013) · Nature · doi:10.1038/nature11935 · Cited by 868
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 777
Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks
Aymard, F., Bugler, B., Schmidt, C. K., Guillou, E., Caron, P., Briois, S., Iacovoni, J. S., Daburon, V., Miller, K. M., Jackson, S. P., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2796 · Cited by 668
PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.206 · Cited by 623
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families
Friedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., & King, M. (1994) · Nature Genetics · doi:10.1038/ng1294-399 · Cited by 622
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 592
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 568
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M. D., Omlin, A. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 564
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 546
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B. S., DeFelice, M. T., Pochanard, P., Ducar, M. D., Hummelen, P. V., MacConaill, L. E., Hahn, W. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 529
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30376-x · Cited by 455
An update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 390
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 362
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 360
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Rulten, S. L., Fisher, A. E. O., Robert, I., Zuma, M. C., Rouleau, M., Ju, L., Poirier, G. G., Reina‐San‐Martin, B., & Caldecott, K. W. (2011) · Molecular Cell · doi:10.1016/j.molcel.2010.12.006 · Cited by 355
Physiology and pathophysiology of poly(ADP‐ribosyl)ation *
Bürkle, A. (2001) · BioEssays · doi:10.1002/bies.1115 · Cited by 337
Treatment of recurrent ovarian cancer
Pignata, S., Cecere, S. C., du Bois, A., Harter, P., & Heitz, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx441 · Cited by 337
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Kummar, S., Kinders, R. J., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J. J., Monks, A. P., Low, J. A., Chen, A. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 328
Genomic Scars as Biomarkers of Homologous Recombination Deficiency and Drug Response in Breast and Ovarian Cancers
Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Aghajanian, C. A., Goff, B. A., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 321
Functions of PARylation in DNA Damage Repair Pathways
Wei, H., & Yu, X. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.05.001 · Cited by 316
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C. U., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 308
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Domchek, S. M., Aghajanian, C. A., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.020 · Cited by 295
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Wang, Y. K., Bashashati, A., Anglesio, M. S., Cochrane, D. R., Grewal, D. S., Ha, G., McPherson, A., Horlings, H. M., Senz, J., Prentice, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3849 · Cited by 268
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
Coleman, R. L., Sill, M. W., Bell‐McGuinn, K. M., Aghajanian, C. A., Gray, H. J., Tewari, K. S., Rubin, S. C., Rutherford, T., Chan, J. K., Chen, A. P., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.042 · Cited by 264
Unraveling the mechanism of BRCA2 in homologous recombination
Holloman, W. K. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2096 · Cited by 230
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
Konecny, G. E., & Kristeleit, R. S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.311 · Cited by 228
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Bitler, B. G., Watson, Z. L., Brubaker, L. W., & Behbakht, K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.003 · Cited by 218
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Colombo, N., Peiretti, M., Parma, G., Lapresa, M., Mancari, R., Carinelli, S. G., Sessa, C., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq244 · Cited by 185
PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination–Mediated DNA Repair
Hu, Y., Petit, S. A., Ficarro, S. B., Toomire, K. J., Xie, A., Lim, E., Cao, S. A., Park, E., Eck, M. J., Scully, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0891 · Cited by 181
A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
Kang, J., D’Andrea, A. D., & Kozono, D. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs177 · Cited by 167
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Drew, Y., Ledermann, J. A., Hall, G. D., Rea, D. W., Glasspool, R. M., Highley, M., Jayson, G. C., Sludden, J., Murray, J., Jamieson, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.41 · Cited by 163
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Matulonis, U. A., Penson, R. T., Domchek, S. M., Kaufman, B., Shapira‐Frommer, R., Audeh, M. W., Kaye, S. B., Molife, L. R., Gelmon, K. A., Robertson, J. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw133 · Cited by 159
Non-homologous end joining: Emerging themes and unanswered questions
Radhakrishnan, S. K., Jette, N., & Lees‐Miller, S. P. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.01.009 · Cited by 136
PARP inhibitors in ovarian cancer
Ledermann, J. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw094 · Cited by 132
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 132
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 131
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E. J., Middleton, M. R., Friedlander, M. L., Gourley, C., Plummer, R., Rustin, G. J. S., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0435-8 · Cited by 129
Repair of Double-Strand DNA Breaks by the Human Nonhomologous DNA End Joining Pathway: The Iterative Processing Model
Ma, Y., Lu, H., Schwarz, K., & Lieber, M. R. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1977 · Cited by 112
Resistance to PARP-Inhibitors in Cancer Therapy
Montoni, A., Robu, M., Pouliot, É., & Shah, G. M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00018 · Cited by 107
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2017) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000404 · Cited by 100
Strategies for Combining Immunotherapy with Radiation for Anticancer Therapy
Seyedin, S. N., Schoenhals, J. E., Lee, D. A., Cortez, M. A., Wang, X., Niknam, S., Tang, C. Z., Hong, D. S., Naing, A., Sharma, P., et al. (2015) · Immunotherapy · doi:10.2217/imt.15.65 · Cited by 93
Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Plummer, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0984 · Cited by 90
Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future
Fields, E. C., McGuire, W. P., Lin, L. L., & Temkin, S. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00177 · Cited by 89
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
Tattersall, A., Ryan, N. A. J., Wiggans, A. J., Rogozińska, E., & Morrison, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007929.pub4 · Cited by 89
Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
von Minckwitz, G., Müller, B. M., Loibl, S., Budczies, J., Hanusch, C. A., Darb‐Esfahani, S., Hilfrich, J., Weiss, E., Huober, J., Blohmer, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9079 · Cited by 85
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
Horton, J. K., Stefanick, D. F., Prasad, R., Gassman, N. R., Kedar, P. S., & Wilson, S. H. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0502 · Cited by 83
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Dhawan, M. S., Bartelink, I. H., Aggarwal, R. R., Leng, J. X., Zhang, J. Z., Pawłowska, N., Terranova-Barberio, M., Grabowsky, J. A., Gewitz, A. D., Chien, A. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0703 · Cited by 79
Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?
Gadducci, A., Fuso, L., Cosio, S., Landoni, F., Maggino, T., Perotto, S., Sartori, E., Testa, A. C., Galletto, L., & Zola, P. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a1cc02 · Cited by 78
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
Bono, J. S. D., Mina, L. A., Gonzalez, M., Curtin, N. J., Wang, E., Henshaw, J. W., Chadha, M. K., Sachdev, J. C., Matei, D. E., Jameson, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2580 · Cited by 76
A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Reiss, K. A., Herman, J. M., ZAHURAK, M. L., Brade, A. M., Dawson, L. A., Scardina, A., Joffe, C., Petito, E., Hacker‐Prietz, A., Kinders, R. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1552 · Cited by 75
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2007) · Nature · doi:10.1038/nature05789 · Cited by 70
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
Mittica, G., Genta, S., Aglietta, M., & Valabrega, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071169 · Cited by 66
Self-citation
Development of PARP inhibitors in oncology
Rodon, J. A., Iniesta, M. D., & Papadopoulos, K. P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802525324 · Cited by 63
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
Reinbolt, R. E., & Hays, J. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00237 · Cited by 62
Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).
Puhalla, S., Beumer, J. H., Pahuja, S., Appleman, L. J., Tawbi, H. A.-H., Stoller, R. G., Lee, J. J., Lin, Y., Kiesel, B. F., Yu, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2570 · Cited by 62
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
Vanderstichele, A., Busschaert, P., Olbrecht, S., Lambrechts, D., & Vergote, I. B. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.029 · Cited by 62
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
Ng, C. K. Y., Cooke, S. L., Howe, K., Newman, S., Xian, J., Temple, J., Batty, E. M., Pole, J. C. M., Langdon, S. P., Edwards, P. A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.3980 · Cited by 59
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Thigpen, J. T. (2012) · Yearbook of Oncology · doi:10.1016/j.yonc.2012.08.001 · Cited by 50
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Dungan, J. S. (2012) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/j.yobg.2012.06.161 · Cited by 48
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
Murata, S., Zhang, C., Finch, N., Zhang, K., Campo, L., & Breuer, E.-K. Y. (2016) · BioMed Research International · doi:10.1155/2016/2346585 · Cited by 47
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study
Landrum, L. M., Brady, W. E., Armstrong, D. K., Moore, K. N., DiSilvestro, P., O’Malley, D. M., Tenney, M. E., Rose, P. G., & Fracasso, P. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.024 · Cited by 42
Hereditary ovarian cancer
Lynch, H. T., Conway, T., & Lynch, J. (1991) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(91)90094-b · Cited by 41
PARP-3, a DNA-dependent PARP with emerging roles in double-strand break repair and mitotic progression
Boehler, C., & Dantzer, F. (2011) · Cell Cycle · doi:10.4161/cc.10.7.15169 · Cited by 36
Phase 1/2 study of oral rucaparib: Final phase 1 results.
Kristeleit, R. S., Burris, H. A., LoRusso, P. M., Patel, M. R., Asghar, U. S., El-Khouly, F., Calvert, H., Infante, J. R., Hilton, J. F., Tolaney, S. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2573 · Cited by 27
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
Nishio, S., Takekuma, M., Takeuchi, S., Kawano, K., Tsuda, N., Tasaki, K., Takahashi, N., Abé, M., Tanaka, A., Nagasawa, T., et al. (2017) · Cancer Science · doi:10.1111/cas.13381 · Cited by 23
Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.
Friedlander, M. L., Gebski, V., Gibbs, E., Bloomfield, R., Hilpert, F., Wenzel, L. B., Joly, F., Eek, D., Rodrigues, M. J., Clamp, A. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5507 · Cited by 18
2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib
Lin, K., Sun, J. X., Maloney, L., Goble, S. M., Oza, A. M., Coleman, R., Scott, C. L., Robillard, L., Mann, E., Isaacson, J., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31469-1 · Cited by 15
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
Matulonis, U. A., Herrstedt, J., Tinker, A. V., Marmé, F., Redondo, A., Kalbacher, E., Ledermann, J. A., Pikiel, J., Christensen, R. D., Berek, J. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5534 · Cited by 14
Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.
Mirza, M. R., Monk, B. J., Gil-Martín, M., Gilbert, L., Canzler, U., Follana, P., Waters, J. S., Kridelka, F., Levy, T., Benigno, B. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5517 · Cited by 10
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
Campo, J. M. D., Mirza, M. R., Berek, J. S., Provencher, D. M., Emons, G., Fabbro, M., Lord, R., Colombo, N., Petru, E., Wenham, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5560 · Cited by 8

Sorted by citations

Discovering Anti-Cancer Drugs via Computational Methods
Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y.-H., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 313
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma
Zhao, Y., Cao, J., Melamed, A., Worley, M. J., Gockley, A. A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 265
Exploiting DNA repair defects in colorectal cancer
Reilly, N. M., Novara, L., Nicolantonio, F. D., & Bardelli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12467 · Cited by 132
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Cecere, S. C., Giannone, G., Salutari, V., Arenare, L., Lorusso, D., Ronzino, G., Lauria, R., Cormio, G., Carella, C., Scollo, P., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.023 · Cited by 108
Self-citation
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
Borella, F., Ghisoni, E., Giannone, G., Cosma, S. D., Benedetto, C., Valabrega, G., & Katsaros, D. (2020) · Diagnostics · doi:10.3390/diagnostics10030146 · Cited by 95
Self-citation

See all 164

Authors: Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G.
Affiliations: Candiolo Cancer Institute (IT)
Corresponding author: Valabrega, Giorgio
ORCID: Ghisoni, Eleonora
Giannone, Gaia
Genta, Sofia
Aglietta, Massimo
Sapino, Anna
Valabrega, Giorgio
Venue: Recent Patents on Anti-Cancer Drug Discovery
Publisher: Bentham Science Publishers Ltd.
Published: 2018-10-03
Volume: 13
Issue: 4
Pages: 392-410
ISSN: 1574-8928 (ISSN-L)
DOI: 10.2174/1574892813666180305165256
OpenAlex: W2794128499
Cited by: 158
References: 100
Citations by year: 2026: 5 · 2025: 16 · 2024: 21 · 2023: 29 · 2022: 20 · 2021: 27 · 2020: 28 · 2019: 11 · 2018: 1
FWCI: 6.28
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
Locations: Recent Patents on Anti-Cancer Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: PARP inhibitors, epithelial ovarian cancer, recurrent ovarian cancer, olaparib, niraparib, rucaparib, talazoparib, veliparib, BRCA mutations, platinum resistance, secondary resistance, mechanism of action, pharmacokinetics, neoadjuvant therapy, first-line therapy, combination therapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Female, Humans, Ovarian Neoplasms, Phthalazines, Piperazines, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PARP Inhibitors in Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks